A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Clinical trial NCT03800134 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03800134
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-06
- Primary completion
- 2022-11-10
- Enrollment
- 825
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.